

**REMARKS**

Entry of the foregoing amendment(s) is respectfully requested.

The claims have been amended to eliminate multiple dependency and to place them in better condition for U.S. patent practice.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: \_\_\_\_\_

Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: February 21, 2001

## CLAIMS

1. Use of a nucleic acid capable of expressing beta-interferon for the preparation of a pharmaceutical composition for the treatment of an immune disease.
2. The use of claim 1, wherein said immune disease is a demyelinating disease.
3. The use of claim 1 or 2, wherein said immune disease is an autoimmune disease.
4. The use of claim 3, wherein said autoimmune disease is multiple sclerosis.
5. The use of anyone of claims 1 to 4, wherein the nucleic acid is DNA.
6. The use of claim 5, wherein the DNA is naked DNA.
7. The use of claim 5, wherein the DNA is associated with a transfection-facilitating vehicle.
8. The use of claim 7, wherein said transfection-facilitating vehicle is selected from the group consisting of viral particles, cationic lipids, cationic polymers and polypeptides.
9. The use of anyone of claims 1 to 8, wherein said beta-interferon is human beta-interferon.
10. The use of anyone of claims 1 to 9, wherein said beta-interferon comprises a secretory signal sequence.
11. The use of anyone of claims 11 to 14, wherein said pharmaceutical composition administration is suitable for administration by injection.